A randomized study of intravesical mitomycin C, bacillus Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder.
Results of a randomized prospective study are reported in which mitomycin C, Tice bacillus Calmette-Guerin (BCG) and RIVM-BCG were compared in 437 patients with primary or recurrent pTa and pT1 bladder tumors, including carcinoma in situ. The followup (or time in study) varied from 2 to 81 months (mean 36 months). After complete transurethral resection of all visible tumors the patients were treated with 30 mg. mitomycin C once a week for 4 consecutive weeks and thereafter every month for a total of 6 months, and 5 x 10(8) colony-forming units Tice BCG or RIVM-BCG once a week for 6 consecutive weeks. For papillary tumors mitomycin C and RIVM-BCG treatments were equally effective (p = 0.53), and mitomycin C was more effective than Tice BCG therapy (p = 0.01).
Vegt
P D
PD
Department of Urology, Rijnland Hospital, Leiderdorp, Bosch Medical Centre, Hertogenbosch, The Netherlands.
Witjes
J A
JA
Witjes
W P
WP
Doesburg
W H
WH
Debruyne
F M
FM
van der Meijden
A P
AP
D000283:Administration, Intravesical; D001500:BCG Vaccine / Q000008:administration & dosage* / Q000009:adverse effects; D002278:Carcinoma in Situ / Q000473:pathology / Q000628:therapy*; D002291:Carcinoma, Papillary / Q000473:pathology / Q000628:therapy*; D005500:Follow-Up Studies; D006801:Humans; D016685:Mitomycin / Q000008:administration & dosage* / Q000009:adverse effects; D009367:Neoplasm Staging; D011446:Prospective Studies; D001749:Urinary Bladder Neoplasms / Q000473:pathology / Q000628:therapy*
D001500:BCG Vaccine; D016685:Mitomycin